<unk> , sold under the brand name Tasmar, is a medication used to treat Parkinson's disease (PD). It is a selective, potent and reversible nitrocatechol-type inhibitor of the enzyme catechol-O-methyltransferase (COMT). It has demonstrated significant liver toxicity, which has led to suspension of marketing authorisations in a number of countries. In comparison with entacapone, another nitrocatechol COMT inhibitor,<unk>  has a longer half life (2.9 hours vs. 0.8 hours) and can better penetrate the blood–brain barrier, acting both in the central nervous system and in the periphery. However, entacapone is less toxic for the liver. Rat catechol-O-methyltransferase bound to<unk> . PDB entry
Tolcapone
Dimethazan
Acolbifene
Lorcaserin
Pretomanid
Quinagolide
Olsalazine
Entropion